^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NKG2D CAR T-cells

    i
    Associations
    News

    Trials

    Company:
    Shanghai Yake Biotech
    Drug class:
    NKG2D-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (NCT04658004)
    Phase 1
    Zhejiang University
    Not yet recruiting
    Last update posted :
    12/08/2020
    Initiation :
    01/15/2021
    Primary completion :
    01/15/2024
    Completion :
    01/15/2027
    NKG2D
    |
    NKG2D CAR T-cells